Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) EBIT: 2022-2025

Historic EBIT for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to -$53.8 million.

  • Centessa Pharmaceuticals' EBIT fell 15.91% to -$53.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.8 million, marking a year-over-year decrease of 32.26%. This contributed to the annual value of -$201.1 million for FY2024, which is 17.38% down from last year.
  • Centessa Pharmaceuticals' EBIT amounted to -$53.8 million in Q3 2025, which was up 1.58% from -$54.7 million recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' EBIT peaked at -$30.8 million during Q1 2025, and registered a low of -$74.6 million during Q4 2024.
  • Moreover, its 3-year median value for EBIT was -$46.4 million (2024), whereas its average is -$46.5 million.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' EBIT spiked by 31.27% in 2023, and later crashed by 112.01% in 2024.
  • Quarterly analysis of 4 years shows Centessa Pharmaceuticals' EBIT stood at -$41.6 million in 2022, then rose by 15.44% to -$35.2 million in 2023, then slumped by 112.01% to -$74.6 million in 2024, then dropped by 15.91% to -$53.8 million in 2025.
  • Its last three reported values are -$53.8 million in Q3 2025, -$54.7 million for Q2 2025, and -$30.8 million during Q1 2025.